Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is now up 55.43% compared to a 12-month low of $6.26. We have seen the price to move -3.66% lower and get settled at $9.73 on 3/14/2019. At recent session, it appeared stuck in a range of $9.69 to $10.17. This company shares are 93.83% off its target price of $18.86 and the current market capitalization stands at $995.08M. The recent change has given its price a -6.57% deficit over SMA 50 and -62.79% deficit over its 52-week high. The stock witnessed 8.72% gains, -17.12% declines and -33.81% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SGMO’s volatility during a week at 4.78% and during a month it has been found around 6.05%.

Sangamo Therapeutics, Inc. (SGMO) Top Holders

Institutional investors currently hold around $647 million or 63.7% in SGMO stock. Look at its top three institutional owners: Blackrock Inc. owns $85.15 million in Sangamo Therapeutics, Inc., which represents roughly 8.56% of the company’s market cap and approximately 13.16% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 7,595,252 shares of the stock are valued at $76.71 million. The third largest holder is State Street Corp, which currently holds $59.69 million worth of this stock and that ownership represents nearly 6% of its market capitalization.

Sangamo Therapeutics, Inc. 13F Filings

At the end of December reporting period, 75 institutional holders increased their position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by some 8,961,356 shares, 120 decreased positions by 10,511,450 and 40 held positions by 44,569,162. That puts total institutional holdings at 64,041,968 shares, according to SEC filings. The stock grabbed 22 new institutional investments totaling 2,524,406 shares while 42 institutional investors sold out their entire positions totaling 2,924,839 shares.

Sangamo Therapeutics, Inc. (SGMO) Analyst Guide

Several analysts have released their opinion on Sangamo Therapeutics, Inc. (NASDAQ:SGMO), with 3 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].